Delfina has secured $17m in a Series A funding round, signalling strong investor confidence in the company’s ability to reshape maternal healthcare through advanced AI technology.
The round was led by US Venture Partners (USVP) and saw participation from ARTIS Ventures, Mayo Clinic, Tokio Marine Future Fund, as well as existing investors including Story Ventures, SemperVirens, Bread and Butter Ventures, Boutique Ventures, and Chelsea Clinton’s Metrodora Ventures.
The San Francisco-based company leverages AI-powered predictive analytics and proactive care interventions to address the alarming maternal health crisis in the United States.
Delfina’s platform seamlessly integrates with primary prenatal care teams to create personalised, data-driven healthcare plans aimed at reducing maternal mortality and improving outcomes for mothers and babies.
With a maternal mortality rate more than twice that of other high-income countries, the U.S. faces a growing crisis, disproportionately impacting Black women, whose maternal mortality rates are nearly triple those of white women.
Delfina’s innovative technology directly tackles these disparities, prioritising equitable access to quality care and addressing unmet social determinants of health.
The newly acquired funding will support Delfina’s national expansion, allowing the company to enhance its predictive technology and interventional support while reaching more patients across the country, including underserved communities.
The company aims to become a leading technology partner for payors, providers, and families, with a focused mission to improve maternal health outcomes and drive systemic change.
Delfina CEO Dr. Senan Ebrahim said, “This funding marks a significant milestone in Delfina’s fulfillment of our mission to solve the national maternal health crisis. We are grateful for the support of our investors and partners who share our commitment to improving outcomes for moms and babies. With this capital, Delfina will accelerate serving diverse populations, evolve our market-leading AI-powered predictive technology, and scale our impact nationally.”
USVP general partner Dafina Toncheva added, “Delfina’s care system is built on the most advanced machine learning technology that creates the most measurable impact for our healthcare system – particularly for Medicaid patients who are so underserved. We are excited to see the lifesaving application of this cutting-edge tech to maternal health. We are thrilled to join Delfina in delivering the future of pregnancy care to all families.”
Copyright © 2025 InsurTech Analyst
